
Diabetic Maculopathy vs Retinopathy: Understanding the Differences
- Posted
- Medically Reviewed by: Mr Mfazo Hove, Consultant Ophthalmic Surgeon
- Author: Mr Mfazo Hove
- Published: November 22, 2024
- Last Updated: November 10, 2026
TL;DR: Diabetic retinopathy is damage to blood vessels in the retina, the light-sensitive layer at the back of the eye, while diabetic maculopathy specifically affects the macula, its central area responsible for reading and detailed vision. You can have retinopathy without maculopathy, and maculopathy can occur at any stage of retinopathy. The distinction matters because the location and type of damage help determine how your vision is affected and whether you need monitoring or treatment.
Retinopathy describes diabetic damage across the retina. Maculopathy identifies involvement of its central area, although your vision may remain good in the early stages.
Diabetic Maculopathy
Diabetic Maculopathy vs Retinopathy at a Glance
Feature | Diabetic Retinopathy | Diabetic Maculopathy |
|---|---|---|
Where | Anywhere in the retina | At the macula |
What happens | Blood vessels leak, become blocked or develop abnormal new growth | Macular oedema, swelling caused by fluid leakage; exudates, deposits left by leaking vessels; or macular ischaemia, reduced blood supply |
Typical symptoms | Often none early on; floaters, dots or lines in your vision, or sudden sight loss if abnormal vessels bleed | Blurred central vision, difficulty reading or distortion, although early changes may cause no symptoms |
Main treatment | Monitoring; laser for proliferative disease, where abnormal new vessels grow; injections or surgery in selected cases | Treatment depends on the type of damage. For swelling, options include monitoring, anti-VEGF injections, laser or steroid implants in selected cases |
Anti-vascular endothelial growth factor (anti-VEGF) injections are medicines that block a signal involved in abnormal blood vessel growth and leakage.
Both conditions arise from diabetic damage to small blood vessels. Retinopathy severity and macular involvement are assessed separately so that each can be monitored and managed.¹ ²
Maculopathy Is Not Always Swelling
Diabetic maculopathy includes macular oedema and macular ischaemia. These can occur together, but they are not the same problem.
Treatment that reduces swelling does not necessarily address reduced blood supply. Your consultant will explain which changes are present and what treatment can realistically achieve.¹
How They Are Graded in Screening
In England, the NHS Diabetic Eye Screening Programme records separate grades for retinopathy and maculopathy. Retinopathy grades run from R0 to R3, with additional subdivisions, while maculopathy is recorded as M0 or M1.
An M1 result means that screening has identified signs requiring further assessment. It does not necessarily confirm macular swelling or mean that treatment is needed.
Lower-risk cases may be assessed through optical coherence tomography (OCT) surveillance, which uses detailed cross-sectional scans of the retina. Higher-risk cases are referred to hospital eye services. The appropriate pathway also depends on the retinopathy grade and scan findings.²
How Diabetic Maculopathy and Retinopathy Are Treated
Diabetic Maculopathy
When swelling involves the centre of the macula and reduces vision, anti-VEGF injections are often recommended. The decision also depends on retinal thickness and other clinical findings. NICE recommends considering either injections or macular laser in some cases with less retinal thickening. When vision remains good, monitoring or laser may be appropriate.¹
A landmark trial compared aflibercept, bevacizumab and ranibizumab. At one year, aflibercept produced greater average visual improvement in participants whose starting vision was approximately 6/15 or worse. When starting vision was only mildly reduced, average improvements were similar between the three medicines. This finding does not mean that one medicine is best for every patient.³
Proliferative Retinopathy
Panretinal photocoagulation, laser treatment to the peripheral retina outside the central area, is usually the first treatment for proliferative retinopathy. Injections or surgery are used where needed.¹
The Diabetic Retinopathy Study showed that laser reduced the risk of severe vision loss by at least half in high-risk proliferative disease.⁴
Managing Both Conditions
Good long-term blood sugar control and appropriate management of high blood pressure help reduce the risk of diabetic eye disease progressing. Your eye specialist and diabetes care team should consider your eye findings alongside your overall diabetes management.¹
Can You Have One Without the Other?
You can have retinopathy without maculopathy. Retinal changes do not always involve the central area responsible for detailed vision.
Diabetic maculopathy can occur when retinopathy elsewhere is mild, so the overall retinopathy grade alone does not show whether your central vision is at risk. This is why the macula is assessed separately.¹ ²
Understanding Your Screening Letter
Your screening result may include codes such as R1 M0 or R1 M1:
- R describes retinopathy, from R0, no retinopathy, to R3, proliferative retinopathy. Some grades have subdivisions that help determine follow-up.
- M describes maculopathy: M0 means no screening signs of maculopathy, while M1 means signs requiring further assessment.
R1 M1 means background retinopathy with signs suggesting macular involvement. Screening photographs cannot always establish whether the macula is swollen, so an OCT scan helps assess this.
An M1 result does not automatically mean you need injections or another treatment. Depending on the findings, you may remain under OCT surveillance or be referred to hospital eye services.²
Why the OCT Scan Matters
Retinal photographs show surface changes such as haemorrhages, small areas of bleeding, exudates and abnormal new vessels. OCT shows the thickness and structure of the macula and can identify fluid within it.
These images contribute to the assessment alongside your vision and clinical examination. OCT helps show whether swelling involves the centre of the macula, which is important when deciding whether treatment is needed.¹ Our article on OCT Scans explains the test.
When Both Are Present
Maculopathy and more advanced retinopathy can occur together. Anti-VEGF injections can reduce macular swelling and help control abnormal new vessels in selected circumstances, while laser treats proliferative disease.
Your consultant will plan care for each active problem and explain the order in which treatments should be given. Monitoring continues to assess the response and identify further changes.¹
When to Seek Urgent Help
Ask for an urgent GP appointment or contact NHS 111 if you develop new blurred vision, flashing lights, a dark shadow moving across your vision, or a red and painful eye. Do not wait for your next routine screening or clinic appointment.
If you suddenly cannot see from one or both eyes, or develop sudden severe eye pain, go to A&E or call 999. Do not drive yourself.⁵
Frequently Asked Questions
Which is more serious?
Either can threaten sight. Maculopathy can affect central vision used for reading and recognising faces, while proliferative retinopathy can cause bleeding or retinal detachment, where the retina pulls away from the back of the eye.
The seriousness depends on the type and extent of damage. Early assessment and appropriate treatment can help protect vision, but not all existing damage can be reversed.
Can I have maculopathy and still see well?
Yes, particularly early on or when swelling is away from the centre. That is why scans matter: they can reveal changes before you notice symptoms. Your consultant considers the scan findings alongside your vision when deciding between treatment and monitoring.¹
Do I need to see a specialist for R1 M0?
Usually not. Mild background retinopathy without maculopathy is normally monitored through screening. Follow the advice in your screening letter, and seek help sooner if your vision changes.²
Does controlling my diabetes help both?
Yes. Good long-term blood sugar control and management of high blood pressure help reduce the risk of diabetic eye disease progressing. They remain important whether you need monitoring, treatment or both.¹
At Blue Fin Vision®
At our eye clinic, we examine the whole retina and use OCT to assess the macula, so diabetic maculopathy and retinopathy are assessed at the same visit.
Where treatment is needed, injections are given at our Harley Street clinic the same day or the following day, followed by an organised next step with us or through the NHS. Our article on Diabetic Maculopathy explains how the service works.
For more information about the condition and our care:
- Read our article on Diabetic Retinopathy.
- Learn about our Medical Retina service.
Further patient information is available through:
- The Royal National Institute of Blind People (RNIB)’s free Understanding Eye Conditions Related to Diabetes guide.
- Our Patient Information.
Get a clearer understanding of what is affecting your vision. Book a consultation with Blue Fin Vision® for a detailed retinal assessment and advice tailored to your findings, with clinics in London, Hertfordshire & Essex.
References
- National Institute for Health and Care Excellence. Diabetic retinopathy: management and monitoring. NICE guideline NG242. London: NICE; 2024.
- NHS England. Diabetic eye screening: OCT in surveillance pathway [Internet]. GOV.UK; 2025 Apr 16 [cited 2026 Nov 8].
- Diabetic Retinopathy Clinical Research Network; Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193-203.
- Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS report number 8. Ophthalmology. 1981;88(7):583-600.
- NHS. Vision loss [Internet]. 2025 Aug 28 [cited 2026 Nov 8].
ABOUT THE AUTHOR
Mr Mfazo Hove
MBChB MD FRCOphth CertLRS
Consultant Ophthalmic Surgeon | Founder and Medical Director, Blue Fin Vision®
Mr Mfazo Hove is a Consultant Ophthalmic Surgeon with more than two decades of experience across NHS and private practice and more than 57,000 ophthalmic procedures performed. He trained for six and a half years at Moorfields Eye Hospital and served for five years as an NHS consultant at the Western Eye Hospital, Imperial College Healthcare NHS Trust.
He specialises in cataract surgery, refractive lens replacement, laser vision correction and implantable Collamer lenses (ICL). He is the founder and Medical Director of Blue Fin Vision®, a private ophthalmology group providing consultant-delivered care across London, Hertfordshire and Essex. His cataract surgery outcomes are publicly reported through the National Ophthalmology Database.
A ZEISS Key Opinion Leader and international speaker, Mr Hove is a contributing author to The Ophthalmologist and Ophthalmology Times. His writing examines how clinical governance and the organisation of ophthalmic services shape patients’ experiences and outcomes, with a focus on transparent outcome reporting, surgical training and long-term accountability for patient care.


